Inactive Instrument

Kelyniam Global, Inc. Stock Other OTC

Equities

KLYG

US4883591004

Advanced Medical Equipment & Technology

Sales 2022 3.02M Sales 2023 2.67M Capitalization 1.83M
Net income 2022 - Net income 2023 - EV / Sales 2022 0.99 x
Net Debt 2022 560K Net Debt 2023 623K EV / Sales 2023 0.92 x
P/E ratio 2022
-24.8 x
P/E ratio 2023
-8.35 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 53.55%
More Fundamentals * Assessed data
Dynamic Chart
Kelyniam Global Announces NEOS Surgery Cranial LOOP? Fixation System Receives 510(k) Clearance from the FDA for use with Finceramica's CustomizedBone? Hydroxyapatite Cranial Implant CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Singular Health Group Ltd Appoints Kelyniam Global, Inc. and CG1 Solutions as Agents CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Kelyniam Global, Inc. Provides Earnings Guidance for the Year 2022 CI
Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S CI
United States Patent and Trademark Office Issues Notification For Patent Covering the Kelyniam Global's Integrated Fixation Tabs, Currently Marketed as Ifs Tabs or Kwiktabs CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 18-01-08
Director of Finance/CFO - 20-01-31
Chief Operating Officer - 10-12-31
Members of the board TitleAgeSince
Chief Operating Officer - 10-12-31
Corporate Officer/Principal - 14-05-31
Chief Executive Officer - 18-01-08
More insiders
Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company. The Company specializes in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient’s computed tomography (CT) data, the Company’s 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its K-Plans include ke24, ke72 and kp5day. The Company’s emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours.
More about the company